Luminaderm® (NP108) is a non-antibiotic antimicrobial developed for application in a range of topical human health care and consumer (medicated) products and also for animal health.
Developed from the same antimicrobial peptide platform as Novexatin, Novamycin and Novarifyn, Luminaderm is a rapid acting, broad spectrum antimicrobial polymer.
Luminaderm has demonstrated efficacy in nasal decolonisation of Staphylococcus species and outperforms the current "gold standard" decolonisation agent, mupirocin, in its bactericidal activity against methicillin resistant Staphylococcus (MRSA).
Luminaderm is also active against a range of other Gram negative and Gram positive pathogens associated with skin (including wound and burn) infections including P. acnes. Luminaderm is also active against certain fungal pathogens and is particularly effective against Malassezia spp, the organism responsible for dandruff and more serious forms of seborrhea.
Luminaderm is currently in clinical development for animal health applications and has demonstrated efficacy in physiologically relevant systems indicating its potential in a range of large and small animal health indications; particularly relevant as a non-antibitoic antimicrobial solution for food producing livestock.
AB21 9TR, UK
Tel: +44 (0)1224 711377
9121 Anson Way,
North Carolina 27615, US